Patrick Walsh Sells 8,643 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Patrick Walsh sold 8,643 shares of the firm’s stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $86.88, for a total value of $750,903.84. Following the sale, the director directly owned 61,405 shares of the company’s stock, valued at approximately $5,334,866.40. This represents a 12.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

ANI Pharmaceuticals Price Performance

ANIP opened at $81.07 on Wednesday. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $99.50. The firm has a 50-day moving average of $92.15 and a 200 day moving average of $78.37. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. The firm has a market cap of $1.82 billion, a P/E ratio of -105.28 and a beta of 0.54.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm had revenue of $227.81 million for the quarter, compared to analysts’ expectations of $211.92 million. During the same period in the previous year, the company earned $1.34 earnings per share. The company’s quarterly revenue was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Truist Financial increased their price objective on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. HC Wainwright increased their price target on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a research note on Wednesday, September 17th. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. Finally, JPMorgan Chase & Co. upped their price objective on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, September 24th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $99.29.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ANIP. Global Alpha Capital Management Ltd. boosted its stake in ANI Pharmaceuticals by 17.2% in the 2nd quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock worth $56,251,000 after purchasing an additional 126,500 shares during the period. UBS Group AG lifted its holdings in shares of ANI Pharmaceuticals by 45.8% in the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares in the last quarter. Aberdeen Group plc boosted its position in shares of ANI Pharmaceuticals by 76.1% in the first quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock valued at $28,059,000 after acquiring an additional 181,134 shares during the period. Arrowstreet Capital Limited Partnership bought a new position in shares of ANI Pharmaceuticals in the third quarter valued at approximately $32,992,000. Finally, Rubric Capital Management LP grew its stake in ANI Pharmaceuticals by 33.3% during the third quarter. Rubric Capital Management LP now owns 343,414 shares of the specialty pharmaceutical company’s stock valued at $31,457,000 after acquiring an additional 85,745 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.